Truist Securities Initiates Coverage On Perspective Therapeutics with Buy Rating, Announces Price Target of $21
Portfolio Pulse from Benzinga Newsdesk
Truist Securities has initiated coverage on Perspective Therapeutics with a Buy rating and set a price target of $21.

September 25, 2024 | 3:06 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Truist Securities has initiated coverage on Perspective Therapeutics with a Buy rating and a price target of $21, indicating a positive outlook.
The initiation of coverage with a Buy rating and a specific price target of $21 by Truist Securities suggests a positive outlook for Perspective Therapeutics. This is likely to boost investor confidence and potentially drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100